Orgenesis Inc.

ORGS Healthcare Biotechnology

Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.

0.06 0.06 Infinity
Market cap
$5.7M
P/E
0.0×
Fwd P/E
1.0×
Dividend yield
—
F-score
3/9
Altman Z
−352.42
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '24 Sep '24 Jun '24 Mar '24 Older periods
Total current assets
0.76 2.52 2.35 1.96
Total non-current assets
0.59 27.17 28.23 28.96
Total Assets
1.35 29.69 30.58 30.92
Total current liabilities
26.92 36.05 31.70 29.03
Total non-current liabilities
11.96 17.57 14.67 29.44
Total liabilities
38.88 53.62 46.37 58.47
Common Equity (Total)
(37.53) (23.93) (15.79) (27.55)
Shareholders Equity (Total)
(37.53) (23.93) (15.79) (27.55)
Total Debt
16.69 15.14 11.18 26.02

Show all line items

In millions of $ except per-share values · columns are period end dates